November 23rd 2024
The $3.6 million investment will allow the CDMO to boost its advanced labeling, automated visual inspection, and fill/finish capabilities.
Poseida Therapeutics and Takeda Partner to Develop Non-Viral In-Vivo Gene Therapy Programs
October 15th 2021In this collaboration, Takeda will utilize Poseida's biodegradable DNA and RNA nanoparticle delivery technology and other proprietary genetic engineering platforms for the research and development of gene therapies.